| Targeting Wee1 for the treatment of pediatric high-grade gliomas S Mueller, R Hashizume, X Yang, I Kolkowitz, AK Olow, J Phillips, ... Neuro-oncology 16 (3), 352-360, 2014 | 140 | 2014 |
| Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulations M Lohela, AJ Casbon, A Olow, L Bonham, D Branstetter, N Weng, J Smith, ... Proceedings of the National Academy of Sciences 111 (47), E5086-E5095, 2014 | 106 | 2014 |
| Targeted activation in localized protein environments via deep red photoredox catalysis NES Tay, KA Ryu, JL Weber, AK Olow, DC Cabanero, DR Reichman, ... Nature chemistry 15 (1), 101-109, 2023 | 79 | 2023 |
| Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways P Jain, A Silva, HJ Han, SS Lang, Y Zhu, K Boucher, TE Smith, A Vakil, ... Oncotarget 8 (49), 84697, 2017 | 50 | 2017 |
| BRAF status in personalizing treatment approaches for pediatric gliomas A Olow, S Mueller, X Yang, R Hashizume, J Meyerowitz, W Weiss, ... Clinical Cancer Research 22 (21), 5312-5321, 2016 | 48 | 2016 |
| Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma T Dasgupta, AK Olow, X Yang, R Hashizume, TP Nicolaides, M Tom, ... Journal of neuro-oncology 126, 385-393, 2016 | 43 | 2016 |
| LILRB1 blockade enhances bispecific T cell engager antibody–induced tumor cell killing by effector CD8+ T cells A Kim, CJ Han, I Driver, A Olow, AK Sewell, Z Zhang, W Ouyang, JG Egen, ... The Journal of Immunology 203 (4), 1076-1087, 2019 | 39 | 2019 |
| Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma S Mueller, S Bhargava, AM Molinaro, X Yang, I Kolkowitz, A Olow, ... Anticancer research 33 (3), 755-762, 2013 | 39 | 2013 |
| An atlas of the human kinome reveals the mutational landscape underlying dysregulated phosphorylation cascades in cancer A Olow, Z Chen, RH Niedner, DM Wolf, C Yau, A Pankov, EPR Lee, ... Cancer research 76 (7), 1733-1745, 2016 | 33 | 2016 |
| An electroaffinity labelling platform for chemoproteomic-based target identification Y Kawamata, KA Ryu, GN Hermann, A Sandahl, JC Vantourout, AK Olow, ... Nature Chemistry 15 (9), 1267-1275, 2023 | 22 | 2023 |
| Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas T Dasgupta, DA Haas-Kogan, X Yang, A Olow, DX Yang, A Gragg, ... Investigational new drugs 31, 1136-1141, 2013 | 20 | 2013 |
| Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models P Georgiev, ES Muise, DE Linn, MC Hinton, Y Wang, M Cai, L Cadzow, ... Molecular Cancer Therapeutics 21 (3), 427-439, 2022 | 17 | 2022 |
| Proteomic mapping of intercellular synaptic environments via flavin-dependent photoredox catalysis TJ Bechtel, JM Bertoch, AK Olow, M Duich, CH White, T Reyes-Robles, ... Organic & Biomolecular Chemistry 21 (1), 98-106, 2023 | 7 | 2023 |
| Nanoscale mapping of EGFR and c-MET protein environments on lung cancer cell surfaces via therapeutic antibody photocatalyst conjugates T Reyes-Robles, AK Olow, TJ Bechtel, SA Lesley, OO Fadeyi, RC Oslund ACS Chemical Biology 17 (8), 2304-2314, 2022 | 7 | 2022 |
| Peripheral blood biomarkers associated with toxicity and treatment characteristics after 131I-metaiodobenzylguanidine therapy in patients with neuroblastoma K Campbell, EE Karski, A Olow, DA Edmondson, AC Kohlgruber, ... International Journal of Radiation Oncology* Biology* Physics 99 (2), 468-475, 2017 | 7 | 2017 |
| Survival advantage with radiation combined with a selective BRAFV600E inhibitor in an orthotopic, intracranial model of BRAFV600E-mutated high-grade gliomas T Dasgupta, X Yang, R Hashizume, A Olow, I Kolkowitz, W Weiss, ... International Journal of Radiation Oncology, Biology, Physics 84 (3), S125, 2012 | 7 | 2012 |
| Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments AK Olow, L Veer, DM Wolf BMC cancer 21, 1-12, 2021 | 5 | 2021 |
| Survival advantage with Everolimus (RAD001) combined with a selective BRAFV600E Inhibitor in a Xenograft Model of BRAFV600E-mutated Pediatric Glioma T Dasgupta, A Olow, X Yang, T Nicolaides, DA Haas-Kogan Oncology 27 (1), 2013 | 3 | 2013 |
| Functional detection and inhibition of the targetable oncogenic kinome of chemotherapy-treated triple-negative breast cancer cells B Pan, A Olow, Q Sun, M Mori, PRE Lee, M Hartog, C Wang, D Wolf, ... Cancer Research 76, 2016 | 2 | 2016 |
| Correction: LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody–Induced Tumor Cell Killing by Effector CD8+ T Cells A Kim, CJ Han, I Driver, A Olow, AK Sewell, Z Zhang, W Ouyang, JG Egen, ... The Journal of Immunology 203 (7), 2023-2024, 2019 | 1 | 2019 |
Rintaro HashizumeAssociate Professor of Department of Pediatrics, UABยืนยันอีเมลแล้วที่ uab.edu